Flora Hui, PhD, and Pete A. Williams, PhD, recap their article, “Metabolic Dysfunction in Glaucoma: From Bench to Bedside (and Back Again),” which was featured in the January/February issue of Glaucoma Today. IOP lowering treatments are a mainstay of glaucoma management, but, while effective treatments exist, they do not target the neurodegenerative components of the disease. This article discusses the role of metabolic dysfunction in glaucoma and reviews nicotinamide treatment for neuroprotection.